Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL Is a biologically functional cut-point

Journal of Interferon and Cytokine Research

Volumn 34, Issue 7, 2014, Pages 498-504

  Hermanrud, Christina ^a   Ryner, Malin Lundkvist ^a   Engdahl, Elin ^a   Fogdell Hahn, Anna ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BIOLOGICAL MARKER; CHEMOKINE RECEPTOR CCR10; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; CXCL10 PROTEIN, HUMAN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MYXOVIRUS RESISTANCE PROTEIN; TRANSCRIPTOME;

ANTIBODY TITER; ARTICLE; BIOASSAY; CLINICAL ARTICLE; GENE EXPRESSION; GENE EXPRESSION ASSAY; HUMAN; IN VIVO STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; BLOOD; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION; STANDARDS;

ANTIBODIES, NEUTRALIZING; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; CHEMOKINE CXCL10; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; MYXOVIRUS RESISTANCE PROTEINS; POLYMERASE CHAIN REACTION; TRANSCRIPTOME;

EID: 84903778025     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0097     Document Type: Article

References (31)

1. Bertolotto A, Sala A, Caldano M, Capobianco M, Malucchi S, Marnetto F, Gilli F. 2007. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods 321(1-2):19-31. (Pubitemid 46441209)
2. Cepok S, Schreiber H, Hoffmann S, Zhou D, Neuhaus O, von Geldern G, Hochgesand S, Nessler S, Rothhammer V, Lang M, Hartung HP, Hemmer B. 2009. Enhancement of chemo-kine expression by interferon beta therapy in patients with multiple sclerosis. Arch Neurol 66(10):1216-1223.
3. Cohen BA, Oger J, Gagnon A, Giovannoni G. 2008. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 275(1-2):7-17.
4. Deisenhammer F, Reindl M, Harvey J, Gasse T, Dilitz E, Berger T. 1999. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 52(6):1239-1243. (Pubitemid 29177928)
5. Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Capo-bianco M, Bertolotto A. 2006. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 12(1):47-57. (Pubitemid 43169237)
6. Grossberg SE, Kawade Y, Kohase M, Klein JP. 2001a. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 21(9): 743-755. (Pubitemid 32955704)
7. Grossberg SE, Kawade Y, Kohase M, Yokoyama H, Finter N. 2001b. The neutralization of interferons by antibody. I. Quantitative and theoretical analyses of the neutralization reaction in different bioassay systems. J Interferon Cytokine Res 21(9):729-742. (Pubitemid 32955703)
8. Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, Richards SM, Rup B, Shores E, Swanson SJ, Wakshull E. 2007. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 321(1-2): 1-18. (Pubitemid 46454303)
9. Hemmer B, Stuve O, Kieseier B, Schellekens H, Hartung HP. 2005. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 4(7):403-412. (Pubitemid 40826532)
10. Hesse D, Krakauer M, Lund H, Sondergaard HB, Limborg SJ, Sorensen PS, Sellebjerg F. 2011. Disease protection and in-terleukin-10 induction by endogenous interferon-beta in multiple sclerosis? Eur J Neurol 18(2):266-272.
11. Hesse D, Sellebjerg F, Sorensen PS. 2009. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology 73(5):372-377.
12. The IFNB Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4):655-661.
13. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. 2000. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898-904.
14. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brown-scheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al. 1996. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285-294. (Pubitemid 26100751)
15. Jungedal R, Lundkvist M, Engdahl E, Ramanujam R, Westerlind H, Sominanda A, Hillert J, Fogdell-Hahn A. 2012. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler 18(12):1775-1781.
16. Kawade Y. 1986. Quantitation of neutralization of interferon by antibody. Methods Enzymol 119:558-573. (Pubitemid 16025159)
17. Lallemand C, Meritet JF, Erickson R, Grossberg SE, Roullet E, Lyon-Caen O, Lebon P, Tovey MG. 2008. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J Interferon Cytokine Res 28(6):393-404. (Pubitemid 351929939)
18. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402-408. (Pubitemid 34164012)
19. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA. 2004. Recommendations for the design and optimization of immuno-assays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289(1-2):1-16. (Pubitemid 38900899)
20. Pachner AR, Narayan K, Pak E. 2006. Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients. Neurology 66(3):444-446. (Pubitemid 43739958)
21. Paolicelli D, D'Onghia M, Pellegrini F, Direnzo V, Iaffaldano P, Lavolpe V, Trojano M. 2013. The impact of neutralizing antibodies on the risk of disease worsening in interferon beta-treated relapsing multiple sclerosis: a 5 year post-marketing study. J Neurol 260(6):1562-1568.
22. Perini P, Calabrese M, Biasi G, Gallo P. 2004. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 251(3):305-309. (Pubitemid 38387148)
23. Polman C, Kappos L, White R, Dahlke F, Beckmann K, Pozzilli C, Thompson A, Petkau J, Miller D, European Study Group in Interferon Beta-1b in Secondary Progressive MS. 2003. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60(1):37-43. (Pubitemid 36070641)
24. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352(9139):1498-1504.
25. Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Mun-schauer FE, 3rd, Cookfair DL, Simon JH, Jacobs LD. 1998. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 50(5): 1266-1272. (Pubitemid 28240338)
26. Sellebjerg F, Datta P, Larsen J, Rieneck K, Alsing I, Oturai A, Svejgaard A, Soelberg Sorensen P, Ryder LP. 2008. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler 14(5):615-621. (Pubitemid 351954403)
27. Sellebjerg F, Krakauer M, Hesse D, Ryder LP, Alsing I, Jensen PE, Koch-Henriksen N, Svejgaard A, Soelberg Sorensen P. 2009. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol 16(12):1291-1298.
28. Sominanda A, Hillert J, Fogdell-Hahn A. 2008. In vivo bioac-tivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 79(1):57-62.
29. Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A. 2007. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 13(2):208-214. (Pubitemid 46592773)
30. Sorensen PS. 2008. Neutralizing antibodies against interferonBeta. Ther Adv Neurol Disord 1(2):125-141.
31. Sorensen PS, Deisenhammer F, Duda P, Hohlfeld R, Myhr KM, Palace J, Polman C, Pozzilli C, Ross C, Sclerosis ETFoA-I-bAiM. 2005. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12(11):817-827. (Pubitemid 41597593)